COCP - Total Utang marang Modal Cocrystal Pharma Corp

Logo perusahaan publik Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma, Inc. (COCP) operations are independent of market cycles, as combating infections remains a global priority and share prices are driven by test results. Laboratories are implementing robotic dispensers and data analysis software. Reliable raw material supply chains and contractor diversification support high margins. This chart illustrating the price action of the separate_debt_total_eq metric currently shows a level of 1.33.

COCP: Total Utang marang Modal Cocrystal Pharma 04.07.2022 - 29.10.2026

Rincian analitis perusahaan Cocrystal Pharma, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega Cocrystal Pharma|COCP - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Cocrystal Pharma|COCP - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Cocrystal Pharma|COCP - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku cocrystalpharma.com|COCP - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Cocrystal Pharma, Inc.|COCP - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Cocrystal Pharma, Inc.|COCP - Gunggung utang perusahaan|Utang marang nilai buku Cocrystal Pharma|COCP - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Cocrystal Pharma|Rasio cepet cocrystalpharma.com
- informasi bathi lan kelipatan valuasi:
COCP - Asil keuangan resik
Analisis dhasar perusahaan:Cocrystal Pharma
Barang utama Cocrystal Pharma Corp

Operational efficiency dynamics directly impact the 1.33 calculation model, which measures the degree of business dependence on external borrowings relative to equity. Cocrystal Pharma, Inc. (COCP) minimizes its debt load through a low need for headcount expansion by outsourcing clinical trials, which confirms the stable debt-to-equity ratio shown on this chart.

Analisis pesaing Cocrystal Pharma, Inc.

Utang marang Ekuitas Gilead Sciences|Cidara - Utang Agregat marang Ekuitas|Total Utang marang Modal NVAX|CVAC (CureVac Pharma) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal VALN (Valneva SE)|Total Utang marang Modal vir.bio VIR|SIGA - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi EBS (Emergent BioSolutions Inc)|Atea Pharmaceuticals Inc (AVIR) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Invivyd|ENTA (Enanta Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal inovio.com|Rasio Total Utang marang Ekuitas HLVX (HilleVax)|KLRS (Kalaris Therapeutics Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Dyadic International, Inc. - Rasio Total Utang marang Ekuitas|NanoViricides Inc. - Utang marang Ekuitas|Talphera, Inc. - Total Utang marang Modal|Koefisien Total Utang marang Modal Traws Pharma, Inc. TRAW|dwtx.com (DWTX) - Utang marang Ekuitas|Qualigen Therapeutics Inc - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas ALVR|Total Utang marang Modal VBI Vaccines Inc|Utang marang Ekuitas Virios Therapeutics (VIRI)|Koefisien Total Utang marang Modal vaxart.com